Literature DB >> 16465578

Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.

E P Tamm1, E M Loyer, S Faria, C P Raut, D B Evans, R A Wolff, C H Crane, R A Dubrow, C Charnsangavej.   

Abstract

BACKGROUND: Preoperative chemoradiation can potentially improve outcomes in patients with pancreatic cancer. This study addresses its effect on staging pancreatic cancer with multidetector computed tomography (MDCT).
METHODS: Fifty-five patients underwent a dual-phase MDCT pancreas protocol for proved pancreatic cancer. Of these, 16 patients underwent preoperative chemoradiation. Three radiologists independently reviewed images to assess for locally advanced disease, liver and peritoneal metastases on baseline studies of all 55 patients, and on follow-up preoperative studies for the 16 patients receiving preoperative therapy. Overall score for resectability was graded on a scale from 1 to 5 (1, definitely resectable; 5. definitely unresectable). Receiver operating characteristic curves and weighted (kappa statistics were determined.
RESULTS: The areas under the receiver operating characteristic curves for readers 1, 2, and 3 were 0.98, 0.96, and 0.90, respectively. Weighted kappa values for reader 1 versus reader 2, reader 1 versus reader 3, and reader 2 versus reader 3 were 0.90, 0.57, and 0.54, respectively. Interpreting scores of 1 to 3 for resectability as resectable disease, the mean values for sensitivity, specificity, negative predictive value, positive predictive value, and accuracy were 0.92, 0.91, 0.74, 0.98, and 0.92 respectively.
CONCLUSION: The negative predictive value for MDCT for identifying unresectable pancreatic cancer in the setting of preoperative therapy is comparable to that reported in the absence of neoadjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465578     DOI: 10.1007/s00261-005-0194-y

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  16 in total

1.  A decision model of therapy for potentially resectable pancreatic cancer.

Authors:  Jacob P VanHouten; Rebekah R White; Gretchen Purcell Jackson
Journal:  J Surg Res       Date:  2011-09-12       Impact factor: 2.192

2.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

3.  CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.

Authors:  Mathilde Wagner; Celia Antunes; Daniel Pietrasz; Christophe Cassinotto; Magaly Zappa; Antonio Sa Cunha; Oliver Lucidarme; Jean-Baptiste Bachet
Journal:  Eur Radiol       Date:  2016-11-28       Impact factor: 5.315

Review 4.  Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?

Authors:  Thomas B Brunner
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 5.  Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.

Authors:  Marianne Sinn; Marcus Bahra; Timm Denecke; Sue Travis; Uwe Pelzer; Hanno Riess
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

6.  Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Authors:  Mark J Truty; Ryan M Thomas; Matthew H Katz; Jean-Nicolas Vauthey; Christopher Crane; Gaury R Varadhachary; Robert A Wolff; James L Abbruzzese; Jeffrey E Lee; Jason B Fleming
Journal:  J Am Coll Surg       Date:  2012-05-18       Impact factor: 6.113

7.  Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer.

Authors:  Matthew J Reilley; Rachna Shroff; Gauri R Varadhachary
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

8.  Extrahepatic biliary cancer: New staging classification.

Authors:  Dhakshinamoorthy Ganeshan; Fanny E Moron; Janio Szklaruk
Journal:  World J Radiol       Date:  2012-08-28

9.  Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-11-17       Impact factor: 3.452

10.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.

Authors:  Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.